Oncology News | pharmaphorum

News

Merck gets confirmatory trial win for Keytruda in endometria...

Merck & Co’s conditional FDA approval for checkpoint inhibitor Keytruda in endometrial cancer looks secure, thanks to a survival benefit in a confirmatory phase 3 trial.

News

Businessmen trading stocks online. Stock brokers looking at graphs, indexes and numbers on multiple computer screens. Colleagues in discussion in traders office. Business success concept.

Rubius launches $200m IPO to fund red blood cell therapies

Rubius Therapeutics has announced the pricing of its Nasdaq IPO, aiming to raise $200 million towards its novel cell therapies targeting cancer and autoimmune diseases.

News

GSK’s big-ticket cancer alliance with Merck KGaA stumbles ag...

Merck KGaA’s bispecific cancer candidate bintrafusp alfa has failed a second clinical trial in the space of a few weeks, making GlaxoSmithKline’s $4.2 billion licensing deal for the drug lo

News

Sanofi, Regeneron prep filings for Libtayo in cervical cance...

Sanofi and Regeneron’s checkpoint inhibitor Libtayo has become the first immunotherapy to improve survival when used as a second-line therapy in cervical cancer, setting up regulatory filin

News

New era of genomic medicine begins as UK approves Lilly's Re...

The UK regulator has authorised Eli Lilly’s targeted cancer drug Retsevmo for tumours with RET fusion positive lung cancers and thyroid cancers, which the company said could herald a new er

News

Takeda buys Maverick as T-Cell engager research hots up

Takeda is taking its option to buy the privately held biotech Maverick Therapeutics and its T-Cell engager cancer therapies for $525 million, as research into the technology gathers pace.

Merck gets confirmatory trial win for Keytruda in endometria...

Rubius launches $200m IPO to fund red blood cell therapies

GSK’s big-ticket cancer alliance with Merck KGaA stumbles ag...

Sanofi, Regeneron prep filings for Libtayo in cervical cance...

New era of genomic medicine begins as UK approves Lilly's Re...

Takeda buys Maverick as T-Cell engager research hots up

GSK to quit Stevenage for new R&D site in Cambridge

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks